Bing Center for Waldenström's Macroglobulinemia, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
Haematologica. 2010 Mar;95(3):470-5. doi: 10.3324/haematol.2009.010348. Epub 2009 Nov 10.
Hypogammaglobulinemia is common in Waldenström's macroglobulinemia. The etiology of this finding remains unclear, but it has been speculated to be based on tumor-induced suppression of the 'uninvolved' immunoglobulin production
We evaluated the incidence of IgA and IgG hypogammaglobulinemia in 207 untreated patients with Waldenström's macroglobulinemia and investigated the associated clinicopathological findings and impact of therapy. We also sequenced eight genes (AICDA, BTK, CD40, CD154, NEMO, TACI, SH2D1A, UNG) implicated in immunoglobulin deficiency in 19 Waldenström's macroglobulinemia patients with IgA and/or IgG hypogammaglobulinemia.
At baseline 63.3%, 58.0% and 49.3% of the 207 patients had abnormally low serum levels of IgA, IgG, or both. No association between IgA and IgG hypogammaglobulinemia and disease burden, serum IgM levels, beta(2)-microglobulin, International Prognostic Scoring System score, or incidence of recurrent infections was observed, although the presence of adenopathy and/or splenomegaly was associated with a lower incidence of hypogammaglobulinemia. Lower IgA and IgG levels were associated with disease progression in patients managed with a 'watch and wait' strategy. IgA and/or IgG levels remained abnormally low despite response to treatment, including complete remissions. A missense mutation in the highly conserved catalytic site of UNG was observed in a patient with hypogammaglobulinemia, warranting further study of this pathway in Waldenström's macroglobulinemia.
IgA and IgG hypogammaglobulinemia is common in Waldenström's macroglobulinemia and persists despite therapeutic intervention and response. IgA and IgG hypogammaglobulinemia does not predict the risk of recurrent infections in patients with Waldenström's macroglobulinemia, although lower levels of serum IgA and IgG are associated with disease progression in Waldenström's macroglobulinemia patients being managed with a 'watch and wait' strategy.
免疫球蛋白低下血症在华氏巨球蛋白血症中很常见。其病因尚不清楚,但据推测是基于肿瘤诱导的对“未受累”免疫球蛋白产生的抑制。
我们评估了 207 例未经治疗的华氏巨球蛋白血症患者的 IgA 和 IgG 免疫球蛋白低下血症的发生率,并研究了相关的临床病理发现和治疗的影响。我们还对 19 例伴有 IgA 和/或 IgG 免疫球蛋白低下血症的华氏巨球蛋白血症患者的 8 个基因(AICDA、BTK、CD40、CD154、NEMO、TACI、SH2D1A、UNG)进行了测序,这些基因与免疫球蛋白缺陷有关。
在基线时,207 例患者中有 63.3%、58.0%和 49.3%的血清 IgA、IgG 或两者均异常低下。IgA 和 IgG 免疫球蛋白低下血症与疾病负担、血清 IgM 水平、β2-微球蛋白、国际预后评分系统评分或复发性感染的发生率之间无相关性,尽管存在淋巴结病和/或脾肿大与较低的免疫球蛋白低下血症发生率相关。在采用“观察等待”策略治疗的患者中,较低的 IgA 和 IgG 水平与疾病进展相关。尽管治疗反应良好,包括完全缓解,但 IgA 和/或 IgG 水平仍异常低下。在一名免疫球蛋白低下血症患者中观察到 UNG 高度保守催化位点的错义突变,需要进一步研究该途径在华氏巨球蛋白血症中的作用。
IgA 和 IgG 免疫球蛋白低下血症在华氏巨球蛋白血症中很常见,并且即使在治疗干预和反应后也持续存在。在华氏巨球蛋白血症患者中,IgA 和 IgG 免疫球蛋白低下血症并不预示复发性感染的风险,尽管较低的血清 IgA 和 IgG 水平与采用“观察等待”策略治疗的华氏巨球蛋白血症患者的疾病进展相关。